Hemostatic therapy for the treatment of intracranial hemorrhage

Pharmacotherapy

Volumn 28, Issue 4, 2008, Pages 485-495

  Liu DeRyke, Xi ^a   Rhoney, Denise ^b,c  

^a UNIVERSITY OF UTAH   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

^c DETROIT RECEIVING HOSPITAL   (United States)

Author keywords

Hemostatic agent; Intracranial hemorrhage; Recombinant activated factor VII; rFVIIa

Indexed keywords

AMINOCAPROIC ACID; ANTIVITAMIN K; HEMOSTATIC AGENT; RECOMBINANT BLOOD CLOTTING FACTOR 7A; TRANEXAMIC ACID; WARFARIN;

BRAIN EDEMA; BRAIN HEMORRHAGE; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG DOSE COMPARISON; DRUG MONITORING; HEART INFARCTION; HEMOSTASIS; HUMAN; HYDROCEPHALUS; LUNG EMBOLISM; REVIEW; SIDE EFFECT; STROKE; SUBARACHNOID HEMORRHAGE; TRAUMATIC BRAIN INJURY; TREATMENT OUTCOME; TROPONIN BLOOD LEVEL; VENOUS THROMBOEMBOLISM;

AMINOCAPROIC ACIDS; ANTIFIBRINOLYTIC AGENTS; BRAIN INJURIES; CLINICAL TRIALS AS TOPIC; FACTOR VIIA; HEMOSTATICS; HUMANS; INTRACRANIAL HEMORRHAGES; RECOMBINANT PROTEINS; TRANEXAMIC ACID;

EID: 41549128484     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.28.4.485     Document Type: Review

References (75)

1. Broderick JP, Brott TG, Duldner JE, Tomsick T, Huster G. Volume of intracerebral hemorrhage: a powerful and easy-to-use predictor of 30-day mortality. Stroke 1993;24(7):987-93.
2. Brott T, Broderick J, Kothari R, et al. Early hemorrhage growth in patients with intracerebral hemorrhage. Stroke 1997;28(1):1-5.
3. Davis SM, Broderick J, Hennerici M, et al. Hematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage. Neurology 2006;66(8):1175-81.
4. Kazui S, Naritomi H, Yamamoto H, Sawada T, Yamaguchi T. Enlargement of spontaneous intracerebral hemorrhage: incidence and time course. Stroke 1996;27(10):1783-7.
5. Al-Shahi R, You H. Hemostatic drug therapies for acute, nontraumatic intracerebral hemorrhage. Stroke 2007;38(1):204-5.
6. Mannucci PM. Hemostatic drugs. N Engl J Med 1998;339(4):245-53.
7. Roos YB, Rinkel GJ, Vermeulen M, Algra A, van Gijn J. Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev 2003;(2):CD001245.
8. Roos Y, Rinkel G, Vermeulen M, Algra A, van Gijn J. Antifibrinolytic therapy for aneurysmal subarachnoid hemorrhage: a major update of a Cochrane review. Stroke 2003;34(9):2308-9.
9. Manno EM, Atkinson JL, Fulgham JR, Wijdicks EF. Emerging medical and surgical management strategies in the evaluation and treatment of intracerebral hemorrhage. Mayo Clin Proc 2005;80(3):420-33.
10. Mayer SA, Rincon F. Treatment of intracerebral haemorrhage. Lancet Neurol 2005;4(10):662-72.
11. Gebel JM Jr, Jauch EC, Brott TG, et al. Natural history of perihematomal edema in patients with hyperacute spontaneous intracerebral hemorrhage. Stroke 2002;33(11):2631-5.
12. Flibotte JJ, Hagan N, O'Donnell J, Greenberg SM, Rosand J. Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage. Neurology 2004;63(6):1059-64.
13. Aguilar MI, Hart RG, Kase CS, et al. Treatment of warfarin-associated intracerebral hemorrhage: literature review and expert opinion. Mayo Clin Proc 2007;82(1):82-92.
14. Steiner T, Rosand J, Diringer M. Intracerebral hemorrhage associated with oral anticoagulant therapy: current practices and unresolved questions. Stroke 2006;37(1):256-62.
15. Mendelow AD, Gregson BA, Fernandes HM, et al. Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the international surgical trial in intracerebral haemorrhage (STICH): a randomised trial. Lancet 2005;365(9457):387-97.
16. Hart RG, Boop BS, Anderson DC. Oral anticoagulants and intracranial hemorrhage: facts and hypotheses. Stroke 1995;26(8):1471-7.
17. Russell MW, Joshi AV, Neumann PJ, Boulanger L, Menzin J. Predictors of hospital length of stay and cost in patients with intracerebral hemorrhage. Neurology 2006;67(7):1279-81.
18. Roos YB, Beenen LF, Groen RJ, Albrecht KW, Vermeulen M. Timing of surgery in patients with aneurysmal subarachnoid haemorrhage: rebleeding is still the major cause of poor outcome in neurosurgical units that aim at early surgery. J Neurol Neurosurg Psychiatry 1997;63(4):490-3.
19. Solenski NJ, Haley EC Jr., Kassell NF, et al, for the Multicenter Cooperative Aneurysm Study. Medical complications of aneurysmal subarachnoid hemorrhage: a report of the multicenter, cooperative aneurysm study. Crit Care Med 1995;23(6):1007-17.
20. Ohkuma H, Tsurutani H, Suzuki S. Incidence and significance of early aneurysmal rebleeding before neurosurgical or neurological management. Stroke 2001;32(5):1176-80.
21. Naidech AM, Janjua N, Kreiter KT, et al. Predictors and impact of aneurysm rebleeding after subarachnoid hemorrhage. Arch Neurol 2005;62(3):410-16.
22. Kassell NF, Torner JC. Aneurysmal rebleeding: a preliminary report from the cooperative aneurysm study. Neurosurgery 1983;13(5):479-81.
23. Kassell NF, Torner JC, Jane JA, Haley EC Jr, Adams HP. The international cooperative study on the timing of aneurysm surgery. Part 2: surgical results.J Neurosurg 1990;73(1):37-47.
24. Nortje J, Menon DK. Traumatic brain injury: physiology, mechanisms, and outcome. Curr Opin Neurol 2004,17(6):711-18.
25. Stein SC, Smith DH. Coagulopathy in traumatic brain injury. Neurocrit Care 2004;1(4):479-88.
26. Liu-DeRyke X, Rhoney DH. Cerebral vasospasm after aneurysmal subarachnoid hemorrhage: an overview of pharmacologic management. Pharmacotherapy 2006;26(2):182-203.
27. Hillman J, Fridriksson S, Nilsson O, Yu Z, Saveland H, Jakobsson KE. Immediate administration of tranexamic acid and reduced incidence of early rebleeding after aneurysmal subarachnoid hemorrhage: a prospective randomized study. J Neurosurg 2002;97(4):771-8.
28. Sorimachi T, Fujii Y, Morita K, Tanaka R. Rapid administration of antifibrinolytics and strict blood pressure control for intracerebral hemorrhage. Neurosurgery 2005;57(5):837-44.
29. Dandapani BK, Suzuki S, Kelley RE, Reyes-Iglesias Y, Duncan RC. Relation between blood pressure and outcome in intracerebral hemorrhage. Stroke 1995;26(1):21-4.
30. Ohwaki K, Yano E, Nagashima H, Hirata M, Nakagomi T, Tamura A. Blood pressure management in acute intracerebral hemorrhage: relationship between elevated blood pressure and hematoma enlargement. Stroke 2004;35(6):1364-7.
31. Leipzig TJ, Redelman K, Horner TG. Reducing the risk of rebleeding before early aneurysm surgery: a possible role for antifibrinolytic therapy. J Neurosurg 1997;86(2):220-5.
32. Piriyawat P, Morgenstern LB, Yawn DH, Hall CE, Grotta JC. Treatment of acute intracerebral hemorrhage with e-aminocaproic acid. Neurocrit Care 2004;1:47-51.
33. Rice KM, Savidge GF. NovoSeven (recombinant factor VIIa) in central nervous systems bleeds. Haemostasis 1996;26(suppl 1):131-4.
34. Monroe DM, Hoffman M, Oliver JA, Roberts HR. Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol 1997;99(3):542-7.
35. Hoffman M, Monroe DM III. The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis. Semin Hemat 2001;38(4suppl 12):6-9.
36. Pusateri AE, Park MS. Mechanistic implications for the use and monitoring of recombinant activated factor VII in trauma. Crit Care 2005;9(suppl 5):S15-24.
37. Fewel ME, Park P. The emerging role of recombinant-activated factor VII in neurocritical care. Neurocrit Care 2004;1(1):19-29.
38. Mayer SA. Ultra-early hemostatic therapy for intracerebral hemorrhage. Stroke 2003;34(1):224-9.
39. Mayer SA, Brun NC, Begtrup K, et al. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2005;352(8):777-85.
40. Mayer SA, Brun NC, Broderick J, et al. Safety and feasibility of recombinant factor VIIa for acute intracerebral hemorrhage. Stroke 2005;36(1):74-9.
41. Mayer SA, Brun NC, Broderick J, et al. Recombinant activated factor VII for acute intracerebral hemorrhage: US phase IIA trial. Neurocrit Care 2006;4(3):206-14.
42. Sugg RM, Gonzales NR, Matherne DE, et al. Myocardial injury in patients with intracerebral hemorrhage treated with recombinant factor VIIa. Neurology 2006;67(6):1053-5.
43. Subramaniam S, Demchuk AM, Watson T, Barber PA, Hill MD. Unexpected posthemorrhagic hydrocephalus in patients treated with rFVIIa. Neurology 2006;67(6):1096.
44. Mayer SA, Brun N, Broderick J, David S, Diringer M, Steiner T. Safety and preliminary efficacy of recombinant coagulation factor VIIa in acute intracerebral hemorrhage: U.S. phase 2A study [abstract]. Stroke 2004;35:332.
45. Mayer SA. Randomized, placebo-controlled, double-blind phase III study to assess rFVIIa efficacy in acute intracerebral hemorrhage: the FAST trial. Presented at the 16th European stroke conference, Glasgow, United Kingdom, May 29-June 1, 2007. Available from http://www.eurostroke.eu/ esc_gla_highlights.htm#oral%20presentation. Accessed September 25, 2007.
46. Broderick J, Connolly S, Feldmann E, et al. Guidelines for the management of spontaneous intracerebral hemorrhage in adults: 2007 update: a guideline from the American Heart Association/American Stroke Association stroke council, high blood pressure research council, and the quality of care and outcomes in research interdisciplinary working group. Stroke 2007;38(6):2001-23.
47. Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. The pharmacology and management of the vitamin K antagonists: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004;126(suppl 3):204S-33.
48. Deveras RA, Kessler CM. Reversal of warfarin-induced excessive anticoagulation with recombinant human factor VIIa concentrate. Ann Internal Med 2002;137(11):884-8.
49. Levi M, Bijsterveld NR, Keller TT. Recombinant factor VIIa as an antidote for anticoagulant treatment. Semin Hematol 2004;41(suppl 1):65-9.
50. Lee SB, Manno EM, Layton KF, Wijdicks EF. Progression of warfarin-associated intracerebral hemorrhage after INR normalization with FFP. Neurology 2006;67(7):1272-4.
51. Huttner HB, Schellinger PD, Hartmann M, et al. Hematoma growth and outcome in treated neurocritical care patients with intracerebral hemorrhage related to oral anticoagulant therapy: comparison of acute treatment strategies using vitamin K, fresh frozen plasma, and prothrombin complex concentrates. Stroke 2006;37(6):1465-70.
52. Goldstein JN, Thomas SH, Frontiero V, et al. Timing of fresh frozen plasma administration and rapid correction of coagulopathy in warfarin-related intracerebral hemorrhage. Stroke 2006;37(1):151-5.
53. Sorensen B, Johansen P, Nielsen GL, Sorensen JC, Ingerslev J. Reversal of the international normalized ratio with recombinant activated factor VII in central nervous system bleeding during warfarin thromboprophylaxis: clinical and biochemical aspects. Blood Coagul Fibrinolysis 2003;14(5):469-77.
54. Freeman WD, Brott TG, Barrett KM, et al. Recombinant factor VIIa for rapid reversal of warfarin anticoagulation in acute intracranial hemorrhage. Mayo Clin Proc 2004;79(12):1495-500.
55. Ionita CC, Ferrara J, McDonagh DL, Grossi P, Graffagnino C. Systemic hemostasis with recombinant-activated factor VII followed by local thrombolysis with recombinant tissue plasminogen activator in intraventricular hemorrhage. Neurocrit Care 2005;3(3):246-8.
56. Brody DL, Aiyagari V, Shackleford AM, Diringer MN. Use of recombinant factor VIIa in patients with warfarin-associated intracranial hemorrhage. Neurocrit Care 2005;2(3):263-7.
57. Erhardtsen E, Nony P, Dechavanne M, French P, Boissel JP, Hedner U. The effect of recombinant factor VIIa (NovoSeven) in healthy volunteers receiving acenocoumarol to an international normalized ratio above 2.0. Blood Coagul Fibrinolysis 1998;9(8):741-8.
58. Pickard JD, Kirkpatrick PJ, Melsen T, et al. Potential role of NovoSeven in the prevention of rebleeding following aneurysmal subarachnoid haemorrhage. Blood Coagul Fibrinolysis 2000;11(suppl 1):S117-20.
59. Dutton RP, McCunn M, Hyder M, et al. Factor VIIa for correction of traumatic coagulopathy. J Trauma 2004;57(4):709-18; discussion 718-19.
60. Morenski JD, Tobias JD, Jimenez DF. Recombinant activated factor VII for cerebral injury-induced coagulopathy in pediatric patients: report of three cases and review of the literature. J Neurosurg 2003;98(3):611-16.
61. Yusim Y, Perel A, Berkenstadt H, Attia M, Knoller N, Sidi A. The use of recombinant factor VIIa (NovoSeven) for treatment of active or impending bleeding in brain injury: broadening the indications. J Clin Anesth 2006;18(7):545-51.
62. Grounds RM, Bolan C. Clinical experiences and current evidence for therapeutic recombinant factor VIIa treatment in nontrauma settings. Crit Care 2005;9(suppl 5):S29-36.
63. Mohr AM, Holcomb JB, Dutton RP, Duranteau J. Recombinant activated factor VIIa and hemostasis in critical care: a focus on trauma. Crit Care 2005;9(suppl 5):S37-42.
64. Sahander A, Goodnough LT, Ratko T, et al. Consensus recommendations for the off-label use of recombinant human factor VIIa (NovoSeven) therapy. Pharm Ther 2005;30(11):644-58.
65. Poon MC. Pharmacokinetics of factors IX, recombinant human activated factor VII and factor XIII. Haemophilia 2006;12(suppl 4):61-9.
66. Meng ZH, Wolberg AS, Monroe DM III, Hoffman M. The effect of temperature and pH on the activity of factor VIIa: implications for the efficacy of high-dose factor VIIa in hypothermic and acidotic patients. J Trauma 2003;55(5):886-91.
67. Kase CS. Hemostatic treatment in the early stage of intracerebral hemorrhage: the recombinant factor VIIa experience. Stroke 2005;36(10):2321-2.
68. O'Connell KA, Wood JJ, Wise RP, Lozier JN, Braun MM. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA 2006;295(3):293-8.
69. Steiner T, Diringer MN, Schneider D, et al. Dynamics of intraventricular hemorrhage in patients with spontaneous intracerebral hemorrhage: risk factors, clinical impact, and effect of hemostatic therapy with recombinant activated factor VII. Neurosurgery 2006;59(4):767-73; discussion 73-4.
70. Diringer MN, Edwards DF, Zazulia AR. Hydrocephalus: a previously unrecognized predictor of poor outcome from supratentorial intracerebral hemorrhage. Stroke 1998;29(7):1352-7.
71. Tuhrim S, Horowitz DR, Sacher M, Godbold JH. Volume of ventricular blood is an important determinant of outcome in supratentorial intracerebral hemorrhage. Crit Care Med 1999;27(3):617-21.
72. Xi G, Wagner KR, Keep RF, et al. Role of blood clot formation on early edema development after experimental intracerebral hemorrhage. Stroke 1998;29(12):2580-6.
73. Hua Y, Wu J, Keep RF, Nakamura T, Hoff JT, Xi G. Tumor necrosis factor-alpha increases in the brain after intracerebral hemorrhage and thrombin stimulation. Neurosurgery 2006;58(3):542-50; discussion 550.
74. Suo Z, Citron BA, Festoff BW. Thrombin: a potential proinflammatory mediator in neurotrauma and neuro-degenerative disorders. Curr Drug Targets Inflamm Allergy 2004;3(1):105-14.
75. Xi G, Keep RF, Hoff JT. Mechanisms of brain injury after intracerebral haemorrhage. Lancet Neurol 2006;5(1):53-63.